SCHEDULE: TCG Crossover II Amends Tango Therapeutics Stake to 6.3%

TCG Crossover Fund II, L.P., TCG Crossover GP II, LLC, and Chen Yu have filed an amended Schedule 13G, disclosing a 6.3% beneficial ownership in Tango Therapeutics, Inc.

Summary

• TCG Crossover Fund II, L.P., TCG Crossover GP II, LLC, and Chen Yu collectively beneficially own 8,536,196 shares of Tango Therapeutics, Inc. Common Stock.
• This represents 6.3% of the company's outstanding Common Stock.
• The percentage is based on 134,593,998 shares outstanding, as reported by Tango Therapeutics in its Form 10-Q filed with the SEC on November 4, 2025.
• TCG Crossover GP II, LLC is the general partner of TCG Crossover Fund II, L.P., and Chen Yu is the sole managing member of TCG Crossover GP II, LLC, and may be deemed to share voting, investment, and dispositive power.
• The reporting persons expressly disclaim status as a group for purposes of this Schedule 13G.
• The securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of Tango Therapeutics, Inc.

Sentiment

Score: 6

Explanation: The filing is a routine update of beneficial ownership by an institutional investor. The maintenance of a significant stake (6.3%) by TCG Crossover Fund II, L.P. can be interpreted as a neutral to slightly positive signal of continued confidence, but it does not provide new operational or financial information about Tango Therapeutics.

Positives

• A significant institutional investor, TCG Crossover Fund II, L.P., maintains a 6.3% beneficial ownership stake in Tango Therapeutics, Inc., indicating continued investment interest.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding Tango Therapeutics, Inc.'s future performance or operations.

Industry Context

This filing indicates continued institutional investment in Tango Therapeutics, a biotechnology company. Such investments are common in the biotech sector, where capital-intensive research and development often attract specialized funds seeking long-term growth opportunities.

Stakeholder Impact

• Shareholders: Provides transparency regarding significant institutional ownership, confirming a major investor's continued stake.
• Management: Awareness of a significant shareholder's position and the composition of the shareholder base.

Key Dates

Keywords

Tango Therapeutics, TCG Crossover Fund II, Chen Yu, Beneficial Ownership, SEC Filing, Schedule 13G, Common Stock, Institutional Investor, Biotechnology, Healthcare